ALLOCYTE® Plus Advanced
Viable Bone Matrix
ALLOCYTE® Plus Advanced Viable Bone Matrix is a next-
generation cellular bone allograft with viable, bone-derived
progenitor cells and DMSO-free cryoprotectant.
Distinguishing Features
Graft viability post thaw
4 Hours
Thaw in warm saline without decanting for
10 Minutes
Cell viability post-thaw is at least
92%
of initial viable and active cell count
Cells protected by proprietary cryoprotectant
ALLOCYTE® Plus Advanced
Viable Bone Matrix Proprietary
DMSO-free cryoprotectant
2.5% DMSO solution
Cytotoxicity assay showing higher number of viable cells in media containing up to 10% cryoprotectant (left) compared to media containing 2.5% DMSO (right), after 48 hours incubation period.
References
- 1. Data on file.
- 2. Data on file
Keep Up With the Latest Developments
in Surgical and Wound Care Technology
Sign Up for the Sanara MedTech Mailing List
Most Recent Press Releases
Sanara MedTech Inc. Reports Third Quarter 2024 Results
November 13, 2024Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates
November 4, 2024Sanara MedTech Inc. Announces Changes to Its Board of Directors
October 7, 2024"*" indicates required fields
